Physician profile
Van Alan Snider
NPI 1407817190
$1,765.17
in general payments reported to CMS, 2019-2025
21 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $150 · 2021: $245 · 2022: $345 · 2023: $304 · 2024: $319 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $901.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.81 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $158.91 | 2021-2025 | Airsupra |
| Galderma Laboratories, L.P. | $150.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.97 | 2022 | |
| Merck Sharp & Dohme LLC | $102.91 | 2019 | |
| Novo Nordisk INC | $100.27 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.95 | 2025 | Caplyta |
| Exact Sciences Corporation | $74.60 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $37.26 | 2023 | |
| Amgen INC. | $36.77 | 2021-2022 | |
| Allergan, INC. | $31.34 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.53 | 2022 | |
| Supernus Pharmaceuticals, INC. | $22.26 | 2025 | Qelbree |
| Convatec INC. | $19.84 | 2024 | |
| Ironshore Pharmaceuticals INC. | $19.79 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.63 | 2021 | |
| Glaxosmithkline, LLC. | $15.54 | 2021 | |
| Astellas Pharma US INC | $14.56 | 2022 | |
| Esperion Therapeutics, INC. | $12.46 | 2021 | |
| Lilly USA, LLC | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Snider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.